JP2002121138A - Composition for prophylaxis of intestinal tract infectious disease - Google Patents

Abstract

PROBLEM TO BE SOLVED: To obtain a composition for the prophylaxis of intestinal tract infectious diseases capable of carrying out the prophylaxis of the infectious diseases caused by causative bacteria of the intestinal tract infectious diseases. SOLUTION: This composition for the prophylaxis of the intestinal tract infectious diseases comprises one or more kinds selected from the group consisting of oligosaccharides derived from hen's egg yolk, oligosaccharide-bound proteins and oligosaccharide-bound peptides. The composition is especially sialyloligosaccharides, sialyloligosaccharide proteins and sialyloligosaccharide peptides. Furthermore, the composition has inhibitory actions on the adhesion of the causative bacteria of the intestinal tract infectious diseases to host cells.

Description

DETAILED DESCRIPTION OF THE INVENTION

[0001]

TECHNICAL FIELD The present invention relates to a composition for preventing intestinal infections for preventing infections caused by bacteria causing intestinal infections. More specifically, an infectious disease is inhibited by the action of inhibiting the adhesion of intestinal infection-causing bacteria to host cells by an oligosaccharide derived from yolk, an oligosaccharide-binding protein, and an oligosaccharide-binding peptide obtained by treating the oligosaccharide-binding protein with a protease. The present invention relates to a composition for preventing intestinal infections for prevention.

[0002]

2. Description of the Related Art It is generally known that infection by a pathogenic bacterium starts with the attachment of the pathogenic bacterium to a host cell, and induces an infection by multiplication, destruction, and erosion at the site of attachment. Intestinal infectious diseases, such as enterohemorrhagic Escherichia coli, Salmonella, Vibrio parahaemolyticus, V. cholerae, Campylobacter, and Welsh, which cause severe symptoms in humans through infection through the intestinal tract, have been increasing in recent years. The development of vaccines against these infectious diseases has been delayed, and there are problems with their safety. Antibiotics have traditionally been used to treat infections caused by pathogens,
Although the effects of antibiotics are remarkable, their abuse is being restricted in use, for example, causing side effects such as fear of emergence of resistant bacteria. Therefore, it is urgently necessary to develop a component having a preventive effect on infectious diseases, particularly intestinal infectious diseases, and having high safety. Livestock and poultry also have a high incidence of intestinal infections during the suckling period and are often fatal, and thus continue to devastate the livestock and poultry industries. At present, effective preventive and therapeutic methods for these infectious diseases have not yet been developed. Incidentally, sialic acid-containing oligosaccharides exist as oligosaccharide chains present in glycoprotein molecules, oligosaccharide chains present in gangliosides, and oligosaccharide peptides or oligosaccharide chains existing free from glycoproteins or gangliosides. I have. It is known that sialic acid-containing oligosaccharides are present in bird egg yolks by binding to phosvitin molecules (Sha).
inkin, R .; , & Perlmann, G .; E. FIG. ,
Arch. Biochem. Biophys. , 14
5,693-700,1971). In recent years, many studies have revealed the biological significance of sialic acid-containing oligosaccharides. Sialic acid-containing oligosaccharides are present by binding to glycoproteins, retaining the tertiary structure of protein molecules, imparting resistance to proteases, half-life in blood,
It is involved in intermolecular interactions, increased solubility, and the like. Also,
Regarding the biological function of the sialic acid derivative with respect to influenza virus, hemagglutination, expectorant effect (JP-A-61-68418), and protective agent against infection (JP-A-63-2)
No. 84133). In addition, it is known that sialic acid is contained in breast milk 1.5 to 7.0 times that of cow's milk, contributing to immunity of infants, development of brain function, and useful intestinal bacteria. And the effect of promoting the growth of.

[0003]

SUMMARY OF THE INVENTION An object of the present invention is to provide a composition for preventing intestinal infections which prevents infections caused by bacteria causing intestinal infections.

[0004]

Means for Solving the Problems In order to solve the problems of the present invention, the present inventors have conducted intensive studies, and as a result, a group of oligosaccharides, oligosaccharide-binding proteins and oligosaccharide-binding peptides derived from chicken egg yolk. It has been found that the infectious disease caused by intestinal infection-causing bacteria can be prevented by containing at least one member selected from the group consisting of: That is, the present invention includes the following items. (1) A composition for preventing intestinal infectious diseases, comprising at least one member selected from the group consisting of oligosaccharides, oligosaccharide-binding proteins and oligosaccharide-binding peptides derived from chicken egg yolk. (2) The composition for preventing intestinal infection according to (1), wherein the oligosaccharide, oligosaccharide-binding protein and oligosaccharide-binding peptide are sialyl oligosaccharides, sialyl oligosaccharide proteins and sialyl oligosaccharide peptides. (3) The composition for preventing intestinal infection according to (1) or (2), wherein the composition for preventing intestinal infection has an effect of inhibiting the adhesion of intestinal infection-causing bacteria to host cells.

[0005]

DESCRIPTION OF THE PREFERRED EMBODIMENTS Chicken eggs are generally classified into egg whites, egg yolks, eggshells and eggshell membranes, and yolks make up about 30% of the total eggs. Egg yolk contains about 50% moisture, and dried egg yolk powder (dry egg yolk) contains about 60% lipid. Methods for stably obtaining oligosaccharides, oligosaccharide-binding proteins and oligosaccharide-binding peptides used in the composition for preventing intestinal infections of the present invention from chicken egg yolk are described in JP-A-6-245784 and JP-A-8-99988. It can be obtained by the method described above. The yolk as a raw material for obtaining the oligosaccharides, oligosaccharide-binding proteins and oligosaccharide-binding peptides used in the composition for preventing intestinal infections of the present invention from chicken egg yolk is defatted from either raw yolk or dried egg yolk powder without lipids. Egg yolk may be used, and when removing lipids, a solvent (ethanol, acetone, hexane, etc.) that is acceptable under the Food Sanitation Law can be used. As an example of the production method, the water-soluble fraction of defatted egg yolk or the water-soluble fraction obtained by enzymatic treatment of defatted egg yolk is subjected to ultrafiltration and a reverse osmosis membrane to remove high molecular components, and further desalting. It can be obtained by drying the fraction obtained by performing the treatment. The enzymes used here are enzymes such as protease and PNGase (peptide-N-glycanase), the former releasing glycopeptides from glycoproteins and the latter releasing N-glycoside sugar chains from glycoproteins or glycopeptides. It is. PNG
The target oligosaccharide can be obtained easily and in high yield simply by adding powder or paste of almond or apricot seed containing PNGase as well as purified product. The sialyl oligosaccharide, sialyl oligosaccharide binding protein and sialyl oligosaccharide binding peptide derived from chicken egg yolk of the present invention are represented by the following general formula. Moreover, the oligosaccharides, oligosaccharide-binding proteins and oligosaccharide-binding peptides derived from chicken eggs of the present invention are obtained by removing terminal sialic acid (NeuAc) by enzymatic treatment or acid treatment.

[0006]

Embedded image

[Wherein, R represents a sugar residue, a glycopeptide residue or a glycoprotein residue. X1 and X2 are NeuAc
(Α2,6) Gal (β1,4) GlcNAc (β1,
2)-, Gal (β1,4) GlcNAc (β1,2)
-Or GlcNAc (β1,2)-. Also, X
1 and X2 may be the same or different. However, one of X1 and X2 is at least NeuAc (α2,6) Gal (β1,4) GlcN
Ac (β1,2)-is shown. Man indicates mannose, NeuAc indicates sialic acid (N-acetylneuraminic acid), Gal indicates galactose, and GlcNAc indicates N-acetylglucosamine. 』

The intestinal infectious diseases of the present invention include enterohemorrhagic Escherichia coli, salmonella, intestinal vibrio, cholera, campylobacter, etc., which are transmitted through the intestinal tract to humans, livestock and livestock.
It means an infection that causes serious symptoms in poultry pets, etc.
Salmonell as the causative bacteria causing these
a enteritidis, Escherichi
a coli, Vibrio parahaemol
yticus, Vibrio cholerae,
Campylobacter jejumi, Camp
Bacteria such as ylobacter coli. The amount of the oligosaccharide, oligosaccharide-binding protein and oligosaccharide-binding peptide in the intestinal infection preventive composition of the present invention is not particularly limited, and the excipient, flour usually used as a bulking agent, It can be used with starch, dextrin, glucose, lactose, cellulose, trehalose and the like. The obtained composition for preventing intestinal infection can be used as dragees, tablets, syrups or capsules. In addition, various foods and drinks, for example,
Soft drinks, milk drinks, fruit drinks, fermented drinks, jelly, pudding, ice cream, yogurt, candy, chewing gum, baked goods such as biscuits and cookies,
It can be blended with bakery products such as breads and cakes, buns, dumplings, Japanese sweets, ramen, udon noodles, soups, prepared foods, baby powdered milk, and other usual forms of food. It can also be used by blending it with feed for livestock, poultry, and pets. The oligosaccharides, oligosaccharide-binding proteins and oligosaccharide-binding peptides that are components of the present invention are derived from the egg yolk of chicken eggs and have no adverse effect on the human body when taken orally, and have a long length. The period of intake is also possible, and the amount of intake is not particularly limited, but an intake of about 0.1 to 150 mg / kg body weight / day is appropriate, and preferably 1 to 100 mg / kg.
Weight / day. The number of times of eating may be once a day, or may be divided into several times. 1,500mg
No side effects or other disorders were observed at a dose of / kg body weight / day. In addition, the amount of addition when blended in foods and the like may be 0.001% or more, and is preferably 0.01% or more. Hereinafter, the present invention will be described in more detail with reference to Examples, but the present invention is not limited thereto.

[0009]

[Embodiment 1] Preparation of Sialyl Oligosaccharide, Sialyl Oligosaccharide Peptide, Sialyl Oligosaccharide Protein Mixture Eight tons of ethanol was added to 2 tons of yolk powder (manufactured by Sanobo), and after sufficient stirring, 1 ton of defatted egg yolk was obtained on the solids side with a screw decanter. Was. Five tons of water was added to one ton of defatted egg yolk, and the mixture was heated to 50 ° C. while stirring with a homomixer. After uniformly dispersing, 5 kg of protease A (manufactured by Amano Pharmaceutical Co., Ltd.) was added and reacted for 8 hours. Enzyme reaction solution is 90
After heating to ℃ to deactivate the enzyme, insolubles were removed by a filter press. The filtrate was subjected to an ultrafiltration apparatus to remove a high molecular fraction. 5 tons of the filtrate were fractionated with a molecular weight of 20,
Sialyl oligosaccharide, sialyl oligosaccharide peptide and sialyl oligosaccharide protein were collected at a rate of 90% or more while passing through a membrane of No. 000 (manufactured by Nitto Denko Corporation) and confirming the resorcinol method, which is a colorimetric analysis method for sialic acid. The operation of ultrafiltration was completed as an end point. To desalt 5 tons of the permeate obtained by the ultrafiltration operation, use 500 L of cation resin.
After sufficient stirring, the cation resin and the peptides and salts adsorbed on the cation were removed. 6 tons of the desalted liquid is evaporated to dryness with a vacuum concentrator to obtain sialyl oligosaccharide,
300 kg of a composition containing a sialyl oligosaccharide peptide and a sialyl oligosaccharide protein was obtained.

Embodiment 2 Preparation of Sialyl Oligosaccharide Peptide 50 kg of defatted egg yolk powder is suspended in 250 liters of water,
Stir at room temperature for 3 hours. After filtration, the mixture was allowed to stand at 4 ° C. for 2 days to remove trace amounts of insolubles, and a supernatant was obtained. The obtained supernatant was concentrated to 50 liters by a reverse osmosis membrane (RO membrane). The concentrated solution is converted to an anion exchange resin (manufactured by Dow Chemical, MSA-
1) Adsorbed to 250 liters, washed with 500 liters of water, and eluted with 50 mM NaCl aqueous solution. 50 mM
The NaCl eluted fraction was concentrated, desalted, and dried to obtain 14 g of a sialyl oligosaccharide peptide. The purity was confirmed by HPLC to be 91%.

Embodiment 3 Preparation of Sialyl Oligosaccharide Peptide A phenol: water mixture (9: 1, w / w) was added to a diluted yolk solution obtained by adding an equal amount of water to 50 kg of fresh yolk, and the mixture was vigorously stirred. Water was further added to the obtained emulsion to prepare a diluent, which was then centrifuged (6000 rpm, 30 rpm).
Min), the obtained supernatant was concentrated under reduced pressure. The precipitate was further removed, and the supernatant was passed through a gel filtration column (Sephadex G-5).
0, 0.1 M NaCl) to separate a sialic acid reaction positive fraction. The same operation was repeated on the obtained fraction on the same column to remove impurities. After desalting the obtained fraction,
Anion exchange column (DEAE Toyopearl)
650 M, 5 mM Tris-HCl buffer, pH8.
0), and the sialic acid reaction-positive fraction was separated as a sialyl oligosaccharide peptide, separated, desalted and freeze-dried to obtain 21.1 g.
I got When the purity was confirmed by HPLC, it was 98%.

Embodiment 4 FIG. Preparation of sialyl oligosaccharide 40 kg of defatted egg yolk powder is suspended in 200 liters of water,
Stir at room temperature for 3 hours. After filtration, the mixture was allowed to stand at 4 ° C. for 2 days to precipitate a small amount of insolubles, thereby obtaining a supernatant. The obtained supernatant is subjected to reverse osmosis membrane (NTR-7410, manufactured by Nitto Denko).
And concentrated to 20 liters. P of the obtained concentrate
H was adjusted to 5.0 and 40 g of defatted almond powder was added, followed by stirring at 37 ° C. for one day. The obtained liquid was filtered, and an anion exchange resin (manufactured by Dow Chemical, Dowex 1 × 8) was used.
Adsorbed to 100 liters. This was washed with 200 liters of water, and then gradient-eluted with a 0 to 0.15 M aqueous sodium acetate solution. The fraction of 0 to 0.06 M was concentrated, desalted and dried to obtain 1.4 g of sialyl oligosaccharide. The purity was confirmed by HPLC to be 93%.

Embodiment 5 FIG. Preparation of sialyl oligosaccharide 100 kg of defatted egg yolk powder was suspended in 500 liters of water and stirred at room temperature for 3 hours. After filtration, the mixture was allowed to stand at 4 ° C. for 2 days to precipitate a small amount of insolubles, thereby obtaining a supernatant.
The obtained supernatant is subjected to a reverse osmosis membrane (Nitto Denko, NTR-741).
Concentrate to 50 liters using 0). The pH of the obtained concentrate was adjusted to 5.0, and defatted almond powder was added to 700.
g was added and stirred at 37 ° C. for 1 day. The obtained liquid was filtered, and an anion exchange resin (manufactured by Dow Chemical, Dowex1) was used.
× 8) Adsorbed to 250 liters. This was washed with 500 liters of water, and then eluted with a 0 to 0.3 M NaCl aqueous solution. 0.05-0.1M NaCl
Was concentrated, desalted, and dried to obtain 29.5 g of sialyl oligosaccharide. When the purity was confirmed by HPLC, it was 95%.
Met.

Embodiment 6 FIG. Preparation of sialyl oligosaccharide 100 kg of defatted egg yolk powder was suspended in 500 liters of water and stirred at room temperature for 3 hours. After filtration, the mixture was allowed to stand at 4 ° C. for 2 days to precipitate a small amount of insolubles, thereby obtaining a supernatant.
The obtained supernatant is subjected to a reverse osmosis membrane (Nitto Denko, NTR-741).
Concentrate to 50 liters using 0). The pH of the obtained concentrate was adjusted to 5.0, and 700 g of defatted apricot seeds were added.
The mixture was stirred at 37 ° C. for one day. The obtained liquid was filtered, and an anion exchange resin (manufactured by Dow Chemical, Dowex 1 × 8) 25
It was adsorbed to 0 liter. This was washed with 500 liters of water, and then eluted with a 0 to 0.3 M NaCl aqueous solution. The fraction of 0.05 to 0.1 M NaCl was concentrated, desalted, and dried to obtain 27.2 g of sialyl oligosaccharide. The purity was confirmed by HPLC to be 92%.

Embodiment 7 FIG. Preparation of sialyl oligosaccharide 10 g of the sialyl oligosaccharide peptide obtained in Example 3 was dissolved in a 0.25 M phosphate buffer, and PNGase (pe
ptide-N4- (N-acetyl-β-gluc
osainyl) asparagine amidas
e) was added and reacted at 37 ° C. for 16 hours. The released peptides and sugar chains were subjected to gel filtration (Sephadex G-50, 0. 0).
(1M NaCl) and sialyl oligosaccharides.
8 g were obtained. The purity was confirmed to be 99.2 by HPLC.
%Met.

Embodiment 8 FIG. Preparation of sialic acid-removed oligosaccharide (asiarocyanyl oligosaccharide) The sialyl oligosaccharide solution obtained in Example 7 (2% solution,
Neuraminidase (Arthrobacter ureafac) was added to 50 ml of 50 mM acetate buffer, pH 5.5.
iens-derived, 500 mU), and reacted at 37 ° C. for 15 hours. The reaction solution was subjected to gel filtration (Sephadex G-
25) Purification and desalting using a column, and the obtained fraction was dried to remove sialic acid.
7 g were prepared. When the purity was confirmed by HPLC, it was 9
9.8%.

Embodiment 9 Preparation of Intestinal Infectious Disease Prevention Composition (Capsule) Spray-dried lactose 188 g, corn starch 18.8 g, polyvinylpyrrolidone 3.2 g, sialyl oligosaccharide obtained in Example 1, sialyl oligosaccharide peptide, sialyl oligosaccharide protein mixture 30 g Was uniformly mixed in accordance with the formulation of the above, and 400 mg of the mixture was filled in a gelatin capsule. One capsule contains 50 mg of a sialyl oligosaccharide, a sialyl oligosaccharide peptide, and a sialyl oligosaccharide protein mixture, which are the active ingredients of the present invention.

Embodiment 10 Preparation of Intestinal Infectious Disease Prevention Composition (Tablets) After uniformly mixing according to the formulation of corn starch 19 mg, crystalline cellulose 30 mg, magnesium stearate 1 mg, lactose 80 mg, and sialyl oligosaccharide peptide 20 mg obtained in Example 2, compression molding was performed. And one tablet 15
0 mg tablets were prepared. This tablet contains 20 mg of the sialyl oligosaccharide peptide which is the active ingredient of the present invention.

Embodiment 11 FIG. Preparation of Intestinal Infectious Disease Prevention Composition (Syrup) 350 g of sugar, 200 g of sorbitol, 0.2 g of methyl paraoxybenzoate, 0.2 g of propyl paraoxybenzoate.
15 g, sodium citrate 8 g, citric acid 1.2 g,
A syrup solution was prepared by dissolving and mixing a small amount of flavor, 2 g of the sialyl oligosaccharide peptide obtained in Example 6, and 438 g of purified water according to the formulation. 50 g of this syrup solution contains 100 mg of the sialyl oligosaccharide peptide of the present invention.

Embodiment 12 FIG. Preparation of Intestinal Infectious Disease Prevention Composition (Agar Jelly) 12 g of agar, 500 g of sugar, 300 g of starch syrup, 500 of water
An agar jelly was prepared according to a conventional method using a mixed formulation of 9.5 g of the sialyl oligosaccharide obtained in Example 7 and a small amount of flavor and Western liquor, and cut into an appropriate size. Finished yield is 95
It was 0 g. 20 mg of this agar jelly contains 200 mg of the sialyl oligosaccharide of the present invention.

Test Example 1 Intestinal infection-induced adhesion inhibition experiment using cultured human intestinal tract cells As the intestinal infection-causing bacteria, Salmonella enteritidis, a clinical strain of diarrhea protozoa, was used.
teritidis), and E. coli K-88 (E.
coli K-88) was used. The samples were yolk-derived sialyl oligosaccharide peptides (sialyl oligosaccharide peptides prepared in Example 3), sialyl oligosaccharides (sialyl oligosaccharides prepared in Example 7), and asialocyanyl oligosaccharides (asialyalyl oligosaccharides prepared in Example 8). Sugar) was used. Salmonella and Escherichia coli pre-cultured to the exponential growth phase were used, and human intestinal epithelial cells Caco-2 cells were used for monolayer culture in a 24-well microplate for 10 to 14 days. Egg yolk-derived sialyl oligosaccharide peptide (sialyl oligosaccharide peptide prepared in Example 3), sialyl oligosaccharide (sialyl oligosaccharide prepared in Example 7), and asialocyanyl oligosaccharide (asialiaryl oligosaccharide prepared in Example 8) Is C at a concentration of 100 μM or 1 mM.
aco-2 added from the apical side of the cell 60
Incubated for minutes. Its 10 ⁶ -10 ⁷ / wel
1 of the infection-causing bacterium was added from the apical side,
Incubated for minutes. After washing the non-adherent bacteria with PBS, the cells were disrupted with PBS containing 0.1% Triton X, serially diluted, and then tryptic soybea.
Nagar was spread, incubated overnight, and the colonies were measured. The adhesion inhibition effect was calculated assuming that the number of control colonies was 100% and the ratio was 100%. Regarding the effect of inhibiting adhesion to Salmonella and Escherichia coli, any of the tested yolk-derived sialyl oligosaccharide peptides, sialyl oligosaccharides, and asialocyanyl oligosaccharides exhibited an adhesion inhibiting effect. From these results, oligosaccharides in egg yolk
Salmonella enteritidis and E. It has been found that it has an adhesion inhibitory effect on E. coli and is useful for preventing infectious diseases.

[0022]

[Table 1] Adhesion inhibitory effect on Salmonella

[0023]

[Table 2] Adhesion inhibitory effect on E. coli

Various other embodiments of the present invention will be exemplified below. (1) A composition for preventing intestinal infectious diseases, comprising an oligosaccharide derived from chicken egg yolk. (2) A composition for preventing intestinal infectious diseases, comprising an oligosaccharide-binding protein derived from chicken egg yolk. (3) A composition for preventing intestinal infectious diseases, comprising an oligosaccharide peptide derived from chicken egg yolk. (4) A composition for preventing intestinal infectious diseases, comprising a sialyl oligosaccharide derived from chicken egg yolk. (5) A composition for preventing intestinal infectious diseases, comprising a sialyl oligosaccharide-binding protein derived from chicken egg yolk. (6) A composition for preventing intestinal infectious diseases, comprising a sialyl oligosaccharide peptide derived from chicken egg yolk. (7) The preventive composition for intestinal infection according to any one of (1) to (6), wherein the composition for preventing intestinal infection has an effect of inhibiting adhesion of intestinal infection-causing bacteria to host cells. (8) The intestinal infection-causing bacterium is pathogenic Escherichia coli (1)-
(7) The composition for preventing intestinal infectious disease according to any of the above. (9) The intestinal infection-causing bacterium is Salmonella (1)-
(7) The composition for preventing intestinal infectious disease according to any of the above. (10) The bacterium causing intestinal infection is cholera (1)-
(7) The composition for preventing intestinal infectious disease according to any of the above. (11) The intestinal infection-causing bacterium is Welsh bacteria (1)
To (7) The composition for preventing intestinal infectious disease according to any one of (1) to (7). (12) A medicament comprising the composition for preventing intestinal infectious disease according to any one of (1) to (11). (13) A supplement containing the composition for preventing intestinal infectious disease according to any of (1) to (11). (14) A food containing the composition for preventing intestinal infectious diseases according to any one of (1) to (11). (15) Dragees containing the composition for preventing intestinal infectious diseases according to any of (1) to (11). (16) A bread containing the composition for preventing intestinal infectious disease according to any one of (1) to (11). (17) A cookie containing the composition for preventing intestinal infectious diseases according to any one of (1) to (11). (18) A biscuit containing the composition for preventing intestinal infection according to any one of (1) to (11). (19) A cereal comprising the intestinal infection preventive composition according to any one of (1) to (11). (20) A premix containing the intestinal infection preventive composition according to any of (1) to (11). (21) Noodles containing the intestinal infection preventive composition according to any one of (1) to (11). (22) A tablet comprising the intestinal infection preventive composition according to any one of (1) to (11). (23) A capsule containing the composition for preventing intestinal infectious diseases according to any one of (1) to (11). (24) A Japanese confection containing the composition for preventing intestinal infectious diseases according to any one of (1) to (11). (25) An oral liquid diet containing the composition for preventing intestinal infectious diseases according to any one of (1) to (11). (26) Fried egg containing the composition for preventing intestinal infectious diseases according to any of (1) to (11). (27) An egg boro containing the composition for preventing intestinal infectious disease according to any of (1) to (11). (28) A crepe containing the composition for preventing intestinal infectious disease according to any one of (1) to (11). (29) A cake containing the composition for preventing intestinal infectious diseases according to any one of (1) to (11). (30) A feed for livestock containing the composition for preventing intestinal infectious diseases according to any one of (1) to (11). (31) A feed for poultry containing the composition for preventing intestinal infectious diseases according to any one of (1) to (11). (32) A pet food containing the composition for preventing intestinal infectious diseases according to any of (1) to (11).

[0025]

Industrial Applicability The intestinal infection preventive composition of the present invention can be mass-produced from a hen egg yolk by a very simple method, can safely prevent intestinal infection-causing bacteria without side effects, and can be used industrially. Extremely useful.

──────────────────────────────────────────────────続 き Continued on the front page (51) Int.Cl. ⁷ Identification code FI theme coat ゛ (reference) A61P 43/00 105 A61K 37/02 F term (reference) 4C084 AA02 BA34 CA41 NA14 ZA662 ZB212 ZB352 4C086 AA01 AA02 EA01 EA20 MA01 MA04 NA14 ZA66 ZB35 4C087 AA01 AA02 BB33 NA14 ZA66 ZB35

Claims (3)

[Claims] 1. A composition for preventing intestinal infectious diseases, comprising at least one selected from the group consisting of oligosaccharides, oligosaccharide-binding proteins and oligosaccharide-binding peptides derived from chicken egg yolk. 2. The composition according to claim 1, wherein the oligosaccharide, oligosaccharide-binding protein and oligosaccharide-binding peptide are sialyl oligosaccharides, sialyl oligosaccharide proteins and sialyl oligosaccharide peptides. 3. The composition for preventing intestinal infections according to claim 1, wherein the composition has a function of inhibiting adhesion of intestinal infection-causing bacteria to host cells.
The intestinal infection preventive composition according to the above.